Combination of inflammatory and vascular markers in the febrile phase of dengue is associated with more severe outcomes
Life Sciences & Biomedicine - Other Topics
IDAMS)
SELECTION
Adult
Male
0301 basic medicine
medicine
Adolescent
PREDICTION
QH301-705.5
infectious disease
Science
610
PROGRESSION
virus
0601 Biochemistry and Cell Biology
DISEASE
Dengue
Young Adult
03 medical and health sciences
616
Humans
Biology (General)
Preschool
Child
Biology
Inflammation
0303 health sciences
Science & Technology
and the Bill and Melinda Gates Foundation
microbiology
Q
R
biomarkers
SERUM-LEVELS
dengue
BIOMARKER PANEL
3. Good health
HEMORRHAGIC-FEVER
This study was supported by the EU's Seventh Framework Programme (FP7-281803
Case-Control Studies
Child, Preschool
Medicine
Cytokines
Female
the WHO
Life Sciences & Biomedicine
prognostic
Biomarkers
DOI:
10.7554/elife.67460
Publication Date:
2021-06-22T00:00:28Z
AUTHORS (21)
ABSTRACT
Background:Early identification of severe dengue patients is important regarding patient management and resource allocation. We investigated the association of 10 biomarkers (VCAM-1, SDC-1, Ang-2, IL-8, IP-10, IL-1RA, sCD163, sTREM-1, ferritin, CRP) with the development of severe/moderate dengue (S/MD).Methods:We performed a nested case-control study from a multi-country study. A total of 281 S/MD and 556 uncomplicated dengue cases were included.Results:On days 1–3 from symptom onset, higher levels of any biomarker increased the risk of developing S/MD. When assessing together, SDC-1 and IL-1RA were stable, while IP-10 changed the association from positive to negative; others showed weaker associations. The best combinations associated with S/MD comprised IL-1RA, Ang-2, IL-8, ferritin, IP-10, and SDC-1 for children, and SDC-1, IL-8, ferritin, sTREM-1, IL-1RA, IP-10, and sCD163 for adults.Conclusions:Our findings assist the development of biomarker panels for clinical use and could improve triage and risk prediction in dengue patients.Funding:This study was supported by the EU's Seventh Framework Programme (FP7-281803 IDAMS), the WHO, and the Bill and Melinda Gates Foundation.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (56)
CITATIONS (24)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....